Israel Active

Israeli NGO ‘Save a Child’s Heart’ (SACH) has been saving hundreds of lives during the Covid-19 pandemic.

The PlayBeyondBio initiative has selected nine Israeli startups for its program for companies developing solutions for future challenges to healthcare systems. C2i Genomics, Nucleai, Itamar medical, Medial Earlysign, iBex, Octopus.health, Imagene, iCardio.ai and Cordio Medical.

The Israel Institute for Biological Research (IIBR) (see previously) has signed an agreement with Israeli-founded NRx Pharmaceuticals. NRx will complete Phase 2 / 3 trials and commercialize IIBR’s “BriLife” COVID vaccine. Clinical trials will be completed in the Ukraine, Georgia and Israel.

Israel’s Health Ministry has authorized Israel’s healthcare providers to give a third anti-Covid-19 vaccination to adults with impaired immune systems. Israel is the first country to provide boosters to patients who do not develop sufficient antibody response after two doses of the coronavirus vaccine.

Israel’s Medorion uses behavioral intelligence software to provide health insurers with an in-depth understanding of their plan members. It helps the companies retain customers by addressing members’ needs, improving medical conditions and helping members balance health against cost.

Israel’s Cardiac Success is developing a transcatheter ventricular repair device for heart failure patients. The “V-sling” system aims to transform invasive open-heart surgery on patients with Reduced Ejection Fraction (HFrEF) into a safe and effective minimally invasive transcatheter procedure.

Israel’s UltraSight (see previously) is starting clinical trials of its portable ultrasound device in the US and Israel. It will also be tested by Israeli astronaut Eytan Stibbe as part of the Israel Space Agency’s upcoming Rakia mission on the International Space Station.

Israel’s Votis Subdermal Imaging Technologies develops devices to diagnose Peripheral Artery Disease (PAD) affecting 200+ million people globally. The condition affects mainly diabetics and can lead to Chronic limb-threatening ischemia (CLTI) with the subsequent need to amputate the feet.

Researchers at Israel’s Beilinson Hospital have discovered how animal organs can be used in human transplant surgery. The main reason for rejection is the foreign blood vessels that need to be connected to the human body. Coating them with human placenta cells makes a “friendly” interface.

A Tel Aviv University-led international team including Weizmann Institute researchers have developed a nano-film that can generate electricity from any body movement. The non-toxic material could power tiny pacemakers with no need for batteries. It could also power non-medical devices.